Clinical Trials
Currently Recruiting
-
Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering
This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.
This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.
Sponsor: In-House
Principal Investigator: Dr Mark Minden
NCT#: NCT02483312
-
Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy (MET4-IO)Eligible Tumour Type(s): Breast Cancer, Colorectal Cancer, Fallopian Tube Tumours, Malignant Pleural Mesothelioma, Metastatic Melanoma, Ovarian Cancer, Solid Cancer, Squamous Cell Cancer of the Head and Neck, Squamous Cell Carcinoma of the Oral Cavity, Triple Negative Breast Cancer
Sponsor: In-house
Principal Investigator: Lillian Siu & Anna Spreafico(Second PI)
NCT#: NCT03686202
-
Tumor Immunotherapy and MicrobiomE Analysis Project (TIME)Eligible Tumour Type(s): Metastatic Melanoma
Sponsor: In-house
Principal Investigator: Marcus Butler
NCT#: N/A -
Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in PatiEnts with Advanced Solid TumoRs (DAPPER)Eligible Tumour Type(s): Colorectal Cancer, Leiomyosarcoma, Pancreatic Adenocarcinoma
Sponsor: In-house
Principal Investigator: Lillian Siu
NCT#: NCT03851614
-
Prospective Analysis of INteStinal Microbiome and Autoimmune PanEls as PrediCtors of Toxicity in Phase I ImmunOncology Patients (INSPECT-IO)Eligible Tumour Type(s): Solid Cancer
Sponsor: In-house
Principal Investigator: Anna Spreafico
NCT#: NCT04107311
-
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers (LANDMARC)Eligible Tumour Type(s): Epstein-Barr virus- and human papillomavirus -related cancers, Hepatocellular carcinoma
Sponsor: In-house
Principal Investigator: Kathy Han
NCT#: NCT04665388
-
Role of Microbiome as a Biomarker in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 (ROMA LA-OPSCC-2)Eligible Tumour Type(s): Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma
Sponsor: In-house
Principal Investigator: Anna Spreafico
NCT#: NCT03838601
-
1301-02
Phase 1b Study of NY-ESO-1 specific TCR gene transduced autologous T lymphocytes in patients with solid tumors
Sponsor: In-house (in collaboration with Takara Bio Inc)
Principal Investigator: Marcus Butler
NCT#: NCT02869217
Closed Recruiting
-
INSPIRE
INvestigator-initiated Phase II Study of pembrolizumab immunological response evaluation
Sponsor: In-House
Principal Investigator: Lillian Siu
NCT#: NCT02644369
-
ACTIVATE
Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study
Sponsor: In-House
Principal Investigator: Marcus Butler
NCT#: NCT02811497